1-3 of 3
Carolina Terragna, B.S.
Close
Sort by
Journal Articles

Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.

Michele Cavo, M.D., Sara Bringhen, M.D., Nicoletta Testoni, B.S., Paola Omedè, B.S., Giulia Marzocchi, B.S., Marina Ruggeri, B.S., Sandra Durante, B.S., Francesco Di Raimondo, M.D., Davide Rossi, M.D., Ausilia Gorgone, M.D., Francesca Patriarca, M.D., Maria Teresa Petrucci, M.D., Silvia Buttignol, M.D., Anna Levi, M.D., Massimo Offidani, M.D., Chiara Nozzoli, M.D., Roberto Ria, M.D., Barbara Olivero, M.D., Monica Galli, M.D., Vittorio Montefusco, M.D., Vincenzo Callea, M.D., Antonietta Falcone, M.D., Antonio De Vivo, M.D., Mario Boccadoro, MD, Carolina Terragna, B.S., Antonio Palumbo, M.D.
Journal: Blood
Blood (2009) 114 (22): 1868.
https://doi.org/10.1182/blood.V114.22.1868.1868
Published: 2009
Journal Articles

Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.

Elena Zamagni, M.D., Nicoletta Testoni, B.S., Carolina Terragna, B.S., Paola Tacchetti, M.D., Chiara Nicci, B.S., Patrizia Tosi, M.D., Mauro Fiacchini, M.D., Francesca Patriarca, M.D., Francesco Di Raimondo, M.D., Lucio Catalano, M.D., Francesco Casulli, M.D., Silvestro Volpe, M.D., Luciano Masini, M.D., Antonio Ledda, M.D., Annamaria Brioli, M.D., Delia Cangini, M.D., Alessandro Gozzetti, M.D., Catello Califano, M.D., Claudia Cellini, M.D., Affra Carubelli, M.D., Alessandro Petrucci, M.D., Giuliana Leopardi, M.D., Lucia Pantani, M.D., Michela Ceccolini, M.D., Massimo Offidani, M.D., Giulia Perrone, M.D., Michele Baccarani, M.D., Michele Cavo, M.D.
Journal: Blood
Blood (2009) 114 (22): 349.
https://doi.org/10.1182/blood.V114.22.349.349
Published: 2009
Journal Articles

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.

Michele Cavo, M.D., Nicoletta Testoni, B.S., Carolina Terragna, B.S., Giulia Marzocchi, B.S., Sandra Durante, B.S., Renato Zambello, M.D., Chiara Nozzoli, M.D., Lucia Pantani, M.D., Paola Tacchetti, M.D., Luciano Masini, M.D., Michela Ceccolini, M.D., Paola Agostini, M.D., Elena Zamagni, M.D., Valerio De Stefano, M.D., Patrizia Tosi, M.D., Daniele Derudas, M.D., Laura Dessanti, M.D., Stelvio Ballanti, M.D., Salvatore Palmieri, M.D., Andrea Nozza, M.D., Gioacchino Catania, M.D., Jacopo Peccatori, M.D., Alfonso D’Arco, M.D., Pellegrino Musto, M.D., Mariella Grasso, M.D., Maria Caterina Pallotti, M.D., Silvana Pasini, M.D., Pier Paolo Fattori, M.D., Anna Baraldi, M.D., Delia Cangini, M.D., Filippo Ballerini, M.D., Alessandro Petrucci, M.D., Michele Baccarani, M.D.
Journal: Blood
Blood (2008) 112 (11): 1662.
https://doi.org/10.1182/blood.V112.11.1662.1662
Published: 2008